2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11C.04 Retrospective Evaluation of Biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, ARID1A) In Patients with NSCLC IV

EP.11C.04 Retrospective Evaluation of Biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, ARID1A) In Patients with NSCLC IV

Back to course

Pdf Summary

In her retrospective study, Dr. Julia Roeper at the University of Oldenburg explored the impact of various genetic mutations on the effectiveness of immune checkpoint inhibitors (ICIs) in treating patients with metastatic non-small cell lung cancer (mNSCLC). ICIs targeting PD-1 and PD-L1 have improved survival rates in mNSCLC patients, though many patients do not respond adequately to this therapy, indicating the need for additional predictive biomarkers alongside PD-L1.<br /><br />The study involved 505 PD-L1 positive mNSCLC patients identified between 2018 and 2022 in northern Germany. The focus was on genetic mutations including KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, and ARID1A, and their effects on progression-free survival (PFS) and overall survival (OS) with either ICI monotherapy or in combination with chemotherapy. Key demographic and clinical characteristics such as age, sex, smoking status, and PD-L1 expression levels were recorded.<br /><br />The results showed that a significant portion of patients exhibited mutations: TP53 (59%), KRAS (30%), KEAP1 (29%), STK11 (23%), POLE (15%), ARID1A (13%), and PIK3CA (9%). The study found no significant differences in clinical characteristics among different PD-L1 expression groups. It is an initial interim analysis aimed at understanding biomarker distributions among these patients.<br /><br />The study's initial findings aim to determine if these mutations could serve as independent predictive markers for the effectiveness of ICI treatments. Future steps include analyzing OS and PFS across therapy lines and possibly conducting multivariate regression analysis to better understand the relationship between these mutations and treatment outcomes. If significant, this could lead to improved personalization in mNSCLC treatment strategies, optimizing the effectiveness of immunotherapies.

Asset Subtitle

Julia Roeper

Meta Tag

Speaker Julia Roeper

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

genetic mutations

immune checkpoint inhibitors

metastatic non-small cell lung cancer

PD-1

PD-L1

predictive biomarkers

KRAS

TP53

progression-free survival

overall survival